Skip to main navigation
Orchestra BioMed logo

Close

Investor Relations
  • Who We Are
    • Our Approach
    • Our People
    • Careers
  • Our Innovations
    • Pipeline
    • Therapeutic Areas
    • Virtue® SAB
    • BackBeat CNT™
    • FreeHold Retractors
  • Investor Relations
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & Filings
    • SEC Filings
    • Annual Reports and Proxy Satements
  • IR Resources
    • Email Alerts
    • Contact IR
  • Contact Us
Menu - sns
Twitter Linkedin

Investor Relations

News Releases

Orchestra BioMed™ Secures $20 Million Financing Facility from Silicon Valley Bank
December 10, 2019
New York, NY – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank
Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress
December 5, 2019
New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in
Orchestra BioMed™ to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference
November 19, 2019
New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced David P. Hochman, chairman, CEO and founder, will present at the Canaccord Genuity MedTech
Orchestra BioMed™ Strengthens Management Team with Appointments of Expert Product Development Leaders Juan A. Lorenzo and Paul V. Goode, Ph.D.
October 16, 2019
New Hope, PA – Orchestra BioMed ™ ,Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced senior-level appointments to its product development teams.
Orchestra BioMed Announces Late-Breaking Clinical Results Showing BackBeat Cardiac Neuromodulation Therapy™ Drives Significant Reduction in Systolic Blood Pressure
September 28, 2019
Double-blind, randomized trial data demonstrates clinically meaningful and statistically significant difference of 8.1 mmHg in reduction of 24-hour ambulatory systolic blood pressure at 6 months vs. control High responder rate despite 88.5% of treated patients having isolated systolic hypertension
Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease
September 17, 2019
First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease Follows Breakthrough Device designation for Virtue Sirolimus-Eluting Balloon in coronary in-stent restenosis granted in Q2 2019 New Hope, PA – Orchestra
Orchestra BioMed Receives CE Mark for BackBeat Cardiac Neuromodulation Therapy™ (CNT) for Hypertension
September 4, 2019
Late-breaking BackBeat CNT ™  randomized, double-blind clinical results selected by Cardiovascular Research Foundation for presentation at TCT 2019 New Hope, PA – Orchestra BioMed ™ , Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for
Orchestra BioMed™ Completes $34 Million Financing to Accelerate Product Pipeline Development and Advance Partnerships
July 10, 2019
Series B-1 Round Led by Perceptive, RTW and Soleus Capital with Strategic Participation from Terumo Corporation Secures $64 Million in 2019 Capital Inflows, Including $30 Million Upfront Payment from Terumo Partnership Financing Structure Provides Up to an Additional $57 Million in Follow-On
Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon
June 13, 2019
Virtue ®  SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions Terms of the partnership include substantial up-front and milestone payments, equity investment, a strong commitment to global clinical
Orchestra BioMed™ Presents Clinical Data at EuroPCR 2019 Demonstrating Safety and Efficacy of BackBeat Cardiac Neuromodulation Therapy (CNT)
May 23, 2019
Novel implantable bioelectronic treatment delivers immediate, substantial, and sustained reduction in blood pressure Data showed 14.2 mmHg reduction in 24-hour ambulatory systolic blood pressure at three months and 23.4 mmHg reduction in office cuff systolic blood pressure out to two years Therapy

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Next page next ›
  • Last page last »
Displaying 21 - 30 of 47
Orchestra BioMed logo
  • Footerlink - who we are

    Who We Are Our Approach Our People Careers
  • Footerlink - our innovations

    Our Innovations Pipeline Therapeutic Areas Virtue® SAB BackBeat CNT™ FreeHold Retractors
  • Footerlink - news & events

    Investor Relations Overview News & Events Stock Information Corporate Governance Financial & Filings IR Resources
  • Footerlink - contact us

    Contact Us
Menu - sns
Twitter Linkedin

© 2023 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Btn - disclaimer

Disclaimer